Pasithea therapeutics announces positive in vivo preclinical efficacy data for pas-004 from nras mutation cancer xenograft models

Pasithea therapeutics (nasdaq: ktta) announced positive preclinical efficacy in models conducted ahead of its planned phase i, in-human trials in 1q24.
KTTA Ratings Summary
KTTA Quant Ranking